Hints and tips:
Related Special Reports
...Barclays analyst Emily Field believes Anderson must “at a minimum” follow the example of Sanofi, which in October named an earliest date by which it intended to carve out its own consumer healthcare business...
...Alongside Ubben, Bayer nominated Nancy Simonian, the former CEO of US biotech company Syros Pharmaceuticals, and Lori Schechter, the former general counsel of US healthcare group McKesson, to join its supervisory...
...The abandoned asundexian trial “is a major setback for Bayer”, said Markus Manns, a portfolio manager and healthcare expert at Union Investment, Germany’s third-largest asset manager....
...Germany’s Bayer and French giant Sanofi, which makes polio vaccines, have followed suit....
...Metagenomi, a pre-clinical group backed by Moderna and Bayer, priced its $94mn IPO last week at the bottom of its target range, and fell 31 per cent on its first day of trading on Friday....
...“My last drink wasn’t a last hurrah, I had two G&Ts, went to bed and thought, ‘That’s that.’” She found the dry spell made her healthier and happier — so much so, she hasn’t touched a drop since....
...In one of his first meetings with Bayer managers, Anderson played a clip from the film....
...The company’s Ageing Population and Healthcare Innovation ETFs have also fallen out of favour, alongside the L&G Cyber Security Ucits ETF....
...Brewer stepped down abruptly in September after two-and-a-half years in the post. She was replaced by healthcare industry veteran Tim Wentworth....
...Bayer’s criticism of European and British health policies coincided with a visit by Nus Ghani, the UK’s minister of state at the department of business, energy and industrial strategy, to JPMorgan Healthcare...
...healthcare and crop science....
...Gilligan notes that some fixed income trusts trade at a discount while offering “equity-like returns”, highlighting M&G Credit Income with a yield to maturity of 9.2 per cent as an example....
...US healthcare company Johnson & Johnson’s global legal team developed a risk management tool in Asia-Pacific first, in part because it felt those lawyers would be more receptive to innovation than others...
...Over the past two and a half years, buyout groups have struck 150 deals for UK healthcare companies, many of which generate much of their income from providing services to the NHS....
...Plus, the Office for National Statistics House Price Index US: Federal Open Market Committee interest rate announcement Results: Dunelm FY, FedEx Q1, Galliford Try FY, General Mills Q1, M&G H1, Mediobanca...
...“Investors have always worried about government debt and it’s never been a problem, but this time it feels like it’s for real,” said Jim Leaviss, chief investment officer of public fixed income at M&G Investments...
...The head of Bayer’s drugs business warned this week the German company was shifting its pharmaceutical arm’s focus to the US, and away from Britain and European countries that were making “big mistakes”...
...Celltrion Healthcare, a South Korean maker of generic versions of biologic drugs, is preparing to pull a breast cancer treatment from the UK, claiming that the clawback regime wipes out its profit on the...
...Bayer’s pharmaceutical arm is reducing its UK footprint and cutting jobs. Our own domestic titans, GSK and AZ, have chosen to build new factories in countries more friendly to business....
...AbbVie and Eli Lilly have withdrawn from the deal after the German conglomerate Bayer’s pharmaceutical chief executive told the Financial Times on Monday that it was reducing its UK footprint and cutting...
...“The real issue and the concern is that Plan B for an increasing number of women is turning into plan A and ultimately it’s not a medicine that is designed to be plan A,” said Sebastian Guth, Bayer’s president...
...Apply P&G’s trailing multiple and the business could be worth as much as $49bn. That would be a stretch. The US equity capital markets are in a deep freeze....
...Stefan Oelrich, head of Bayer’s drugs business, told the Financial Times that policies such as a medicines levy in the UK and similar schemes in Germany were dissuading investment. 5....
...The UK spends a smaller proportion of its gross domestic product on healthcare than most other OECD countries, he said, and a smaller part of its healthcare budget on drugs....
International Edition